Streetbeat News

Products Services

EFRGF

Pasofino Gold Limited (OTC:EFRGF) has completed its diamond core drilling program at the Bukon Jedeh gold camp within the Dugbe Gold Project in Liberia. The drilling program, which included 11 holes totaling 1,328 meters, revealed encouraging visual results with sulphide-bearing zones. The first batch of samples will be sent to the laboratory in early June, with results expected in July 2024.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 11:40 am

BITF

Bitfarms announced it is on track to deliver 21 EH/s and 21 w/TH in 2024. The company earned 156 BTC in May, which is 42% lower than the previous month and 66% lower year-over-year.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:39 am

NBIX

Neurocrine Biosciences announced positive results from its CAHtalyst Pediatric Phase 3 study on crinecerfont for treating congenital adrenal hyperplasia (CAH). The study met primary and key secondary endpoints, showing significant androgen reduction and glucocorticoid dose reduction while maintaining androgen control. The results were published in The New England Journal of Medicine and presented at ENDO 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:38 am

BIIB

DAL

Biogen Inc. (NASDAQ: BIIB) and Delta Flight Products, a subsidiary of Delta Air Lines, announced a collaboration to enhance air travel for passengers with reduced mobility. This initiative aims to improve the flying experience for approximately 5.5 million wheelchair users in the U.S.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:37 am

ARWR

Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 PALISADE study of investigational Plozasiran, meeting both primary and key secondary endpoints. The company plans to present this data at its June 25, 2024, Cardiometabolic event.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:36 am

BWAY

BrainsWay has received FDA clearance to expand the indication for its Deep Transcranial Magnetic Stimulation (TMS) system to treat patients with major depressive disorder (MDD) aged 22 to 86, up from the previous upper age limit of 68. This is the company's 10th FDA clearance and makes it the first TMS system approved for patients over 68 with MDD, including those with comorbid anxiety symptoms.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:33 am

GPCR

Structure Therapeutics Inc. (NASDAQ:GPCR) announced positive 12-week results from its Phase 2a study of the obesity drug GSBR-1290, showing significant weight loss and favorable safety profiles. The capsule to tablet PK study also demonstrated promising results.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:32 am

JBLU

JetBlue has revised its Q2 revenue outlook slightly upward due to better operational performance and declining jet fuel prices. The company maintains a high completion factor of approximately 99%.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:30 am

AMC

GME

GTLB

NVDA

QQQ

SAIC

SPY

Wall Street is poised for a strong start to June, driven by a resurgence in meme stocks and positive tech sector developments. GameStop and AMC Entertainment saw significant premarket gains due to renewed interest from investors. Nvidia also rose following a keynote address at Computex 2024. Key economic data and manufacturing activity reports are expected to influence market sentiment throughout the week.

Portfolio Pulse from Shanthi Rexaline

June 03, 2024 | 11:29 am

SKT

Tanger Factory Outlet Centers (SKT) plans to open five new Sephora stores in its shopping centers later this year. The new locations will be in Charleston, S.C.; Deer Park, N.Y.; National Harbor, Md.; Palm Beach, Fla.; and Phoenix/Glendale, Ariz.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:24 am